Viagra Research Today is a free monthly online journal that collates and summarizes the latest research about Viagra, including details on sildenafil, erectile dysfunction, impotence, side-effects, alternatives.

Volume 4 (2007), Issue 2 (February)

1. Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men.
   Spinal Cord, 45(2): 169-73. [Abstract] [Full-text]
2. Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.
   Br J Pharmacol, 150(3): 353-60. [Abstract] [Full-text]
3. The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway.
   J Cell Physiol, 211(1): 197-204. [Abstract] [Full-text]
4. Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to ANP in the pregnant rat.
   Am J Physiol Renal Physiol, 292(2): F655-9. [Abstract] [Full-text]
5. Low-dose oral sildenafil for patients with pulmonary hypertension: a cost-effective solution in countries with limited resources.
   Cardiol Young, 17(1): 72-7. [Abstract] [Full-text]
6. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
   Urol Res, 35(1): 49-54. [Abstract] [Full-text]
7. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.
   J Urol, 177(3): 1071-7. [Abstract] [Full-text]
8. Inhibitory effects of sildenafil on gastric motility and gastric slow waves in dogs.
   Neurogastroenterol Motil, 19(3): 218-24. [Abstract] [Full-text]
9. Characterization and functional role of androgen-dependent PDE5 activity in the bladder.
   Endocrinology, 148(3): 1019-29. [Abstract] [Full-text]
10. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Cardiol Rev, 15(2): 76-86. [Abstract] [Full-text]
11. Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666.
    Expert Opin Investig Drugs, 16(3): 393-5. [Abstract] [Full-text]
12. Sildenafil combined with continuous positive airway pressure for treatment of erectile dysfunction in men with obstructive sleep apnea.
    Int Urol Nephrol. [Abstract] [Full-text]
13. A comparison of on-line and off-line sexual risk in men who have sex with men: an event-based on-line survey.
    J Acquir Immune Defic Syndr, 44(2): 235-43. [Abstract] [Full-text]
14. The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners.
    BJU Int, 99(2): 376-82. [Abstract] [Full-text]
15. Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
    Am J Ophthalmol, 143(3): 538-9. [Abstract] [Full-text]
16. Selective blockade of phosphodiesterase types 2, 5 and 9 results in cyclic 3'5' guanosine monophosphate accumulation in retinal pigment epithelium cells.
    Br J Ophthalmol, 91(3): 379-84. [Abstract] [Full-text]
17. The usefulness of simple X-ray powder diffraction analysis for counterfeit control--the Viagra example.
    J Pharm Biomed Anal, 43(4): 1514-8. [Abstract] [Full-text]
18. Optic atrophy after sildenafil use.
    Optometry, 78(3): 122-8. [Abstract] [Full-text]
19. Effect of Catha edulis foresk (khat) extracts on male rat sexual behavior.
    J Ethnopharmacol, 110(2): 250-6. [Abstract] [Full-text]

© 2004-2010 Viagra Research Today. All Rights Reserved.